SaaS Metrics
Academic Publication Minimal residual disease as a target for liquid biopsy in patients with solid tumours
AI Semantic Synergy Context
Connecting this academic literature to real-world market discussions and products.
Minimal residual disease as a target for liquid biopsy in patients with solid tumours
No description provided.
Liquid biopsy in cancer: current status, challenges and future prospects
AbstractCancer has a high mortality rate across the globe, and tissue biopsy remains the gold standard for tumor diagnosis due to its high level of laboratory standardization, good consistency of r...
Liquid Biopsy Based on Cell-Free DNA and RNA
This review delves into the rapidly evolving landscape of liquid biopsy technologies based on cell-free DNA (cfDNA) and cell-free RNA (cfRNA) and their increasingly prominent role in precision medi...
Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges
AbstractCirculating tumor DNA (ctDNA) methylation, an innovative liquid biopsy biomarker, has emerged as a promising tool in early cancer diagnosis, monitoring, and prognosis prediction. As a nonin...
SERS biosensors for liquid biopsy towards cancer diagnosis by detection of various circulating biomarkers: current progress and perspectives
AbstractLiquid biopsy has emerged as a promising non-invasive strategy for cancer diagnosis, enabling the detection of various circulating biomarkers, including circulating tumor cells (CTCs), circ...
Frequently Asked Questions (FAQ)
Curated market intelligence mapped to this research.
What is the core focus of the research titled 'Minimal residual disease as a target for liquid biopsy in patients with solid tumours'?
This literature focuses on:
Are there open-source GitHub repositories related to Minimal residual disease as a target for liquid biopsy in patients with solid tumours?
Yes, open-source projects like MoonshotAI/Attention-Residuals () are actively building upon these concepts.
Which startups are commercializing the technology behind Minimal residual disease as a target for liquid biopsy in patients with solid tumours?
Products like Study OS are bringing this to market. Their focus is: A minimalist focus timer with tasks, notes & study music.
What other academic literature is closely related to 'Minimal residual disease as a target for liquid biopsy in patients with solid tumours'?
Yes, highly correlated activity was mapped. An entry titled 'Minimal residual disease as a target for liquid biopsy in patients with solid tumours' discusses this: No description provided.
Cite this Market Intelligence Report
Reference our AI-mapped synergy between this research and the commercial market to instantly build authority.
Commercial Realization
Startups and Open Source tools heavily associated with the concepts explored in this paper.
-
GitHubMoonshotAI/Attention-Residuals
-
GitHubslavingia/skills
-
Product HuntStudy OS
-
Product HuntFloatPic
Associated Media Narrative
- Imputation-free transformer learning enables robust Alzheimer's disease prediction and calibrated uncertainty quantification across heterogeneous clinical cohorts
- Degree of hypertension and subclinical coronary atherosclerosis in asymptomatic individuals without cardiovascular disease
- AI-guided identification of natural CTSL inhibitors with therapeutic potential for renal injury